Last $11.85 USD
Change Today +0.77 / 6.95%
Volume 19.2K
EBIO On Other Exchanges
As of 8:10 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

eleven biotherapeutics inc (EBIO) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/26/14 - $19.33
52 Week Low
07/28/14 - $9.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

eleven biotherapeutics inc (EBIO) Related Businessweek News

No Related Businessweek News Found

eleven biotherapeutics inc (EBIO) Details

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal product candidate includes the EBI-005, a novel IL-1 receptor antagonist that is in Phase III clinical program for the treatment of moderate to severe dry eye diseases; and in Phase II clinical trial for the treatment of allergic conjunctivitis. The company’s preclinical product candidates comprise EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of retinal diseases, such as diabetic macular edema; and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis, and other diseases of the back of the eye, such as dry age-related macular degeneration. Eleven Biotherapeutics, Inc. has a collaboration and license agreement with ThromboGenics N.V. to identify protein or peptide therapeutics that directly modulate any of a specified set of targets in a novel pathway in retinal disease. The company was founded in 2008 and is based in Cambridge, Massachusetts.

15 Employees
Last Reported Date: 03/31/14
Founded in 2008

eleven biotherapeutics inc (EBIO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $459.4K
Chief Development Officer
Total Annual Compensation: $198.0K
Chief Scientific Officer
Total Annual Compensation: $344.5K
Compensation as of Fiscal Year 2013.

eleven biotherapeutics inc (EBIO) Key Developments

Eleven Biotherapeutics, Inc. Receives Results of Pre-Specified, Masked, Sample Size Reassessment of First Pivotal Phase 3 Clinical Trial of EBI-005 in dry eye disease

Eleven Biotherapeutics, Inc. received the results of a pre-specified, masked, sample size reassessment of first pivotal Phase 3 clinical trial of EBI-005 in dry eye disease. Based on this reassessment, The company will continue to target approximately 650 patients for randomization in this trial as planned. The sample size reassessment was conducted by a contract research organization, or CRO, on a masked basis of the first one-third of the randomized patients when they had completed 12 weeks of masked treatment with EBI-005 or placebo-control. The reassessment was conducted to determine if the observed variability of the clinical response in the ongoing Phase 3 trial was greater than the variability the company assumed based on the results of Phase 1b/2a trial, and whether an increase in the number of patients randomized in this trial would be sufficient to adjust for the increase in variability. The CRO only reported the conclusion of the sample size reassessment to maintain current target of randomizing approximately 650 subjects in this study.

Eleven Biotherapeutics, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Eleven Biotherapeutics, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported collaboration revenue of $761,000 compared to $202,000 a year ago. Loss from operations was $8,045,000 compared to $3,383,000 a year ago. Net loss applicable to common stockholders was $8,121,000 or $0.51 per basic and diluted share against $4,551,000 or $3.44 per basic and diluted share a year ago. For the six months, the company reported collaboration revenue of $1,329,000 compared to $202,000 a year ago. Loss from operations was $15,234,000 compared to $8,818,000 a year ago. Net loss applicable to common stockholders was $15,862,000 or $1.23 per basic and diluted share against $10,956,000 or $8.53 per basic and diluted share a year ago.

Eleven Biotherapeutics, Inc. to Report Q2, 2014 Results on Aug 13, 2014

Eleven Biotherapeutics, Inc. announced that they will report Q2, 2014 results at 8:30 AM, US Eastern Standard Time on Aug 13, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EBIO:US $11.85 USD +0.77

EBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EBIO.
View Industry Companies

Industry Analysis


Industry Average

Valuation EBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 72.3x
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 53.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELEVEN BIOTHERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at